Over the past four years, a remarkable sequencing technology explosion has occurred, opening many new avenues of biological experimentation and discovery. We describe a platform for large-scale sequencing and analysis that extends the incredible potential of next-generation sequencing to transform biomedical research and significantly impact medical practice. Our eight specific aims are intertwined across six major research areas that overall address the NHGRI mission and provide an interdisciplinary approach that is already producing medically relevant results in the areas of cancer genomics, heritable disease, and microbial/metagenomics. Our platform offers a consistently cost-effective approach to sequencing-related research projects and we have established a scalable incoming sample pipeline that can intake and track >40,000 samples per year into a flexible and innovative sequencing pipeline. Equally scalable are our LIMS and analysis pipeline capabilities, having established systems that processed several hundred cancer cases through whole genome sequencing and analysis in the last year alone, along with multiple other project types. We describe a research plan that will further our explorations of human health and disease, in a more comprehensive manner than ever before, and will investigate third-generation sequencing technologies, incorporating their unique attributes and integrating them to our production repertoire. One important aspect of our proposed work includes efforts to begin translating our discoveries and procedures into the clinical setting, effectively setting the stage for genomic diagnosis and personalized medicine. This important transition will be required to bring DNA sequencing to clinical medicine, and our innovative combination of sequencing technology, data analysis, and outstanding clinical collaborators increase the potential for success. Overall, we are enthusiastic about the future of genome sequencing at high scale, and we combine years of success in DNA sequencing and analysis with the necessary collaboration expertise, infrastructure support, and shared vision with NHGRI to make significant progress on these aims in the next four years.
The potential for DNA sequencing to transform medical practice and change our understanding of disease has never been higher. Our group combines years of experience in DNA sequencing with key clinical researchers to address important questions in patient care and outcome. These early efforts will translate to a revolution in medicine, centered around DNA-based diagnostics including whole genome sequencing.
|Cancer Genome Atlas Research Network; Linehan, W Marston; Spellman, Paul T et al. (2016) Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med 374:135-45|
|Gordon, David; Huddleston, John; Chaisson, Mark J P et al. (2016) Long-read sequence assembly of the gorilla genome. Science 352:aae0344|
|Wagner, Alex H; Coffman, Adam C; Ainscough, Benjamin J et al. (2016) DGIdb 2.0: mining clinically relevant drug-gene interactions. Nucleic Acids Res 44:D1036-44|
|Hundal, Jasreet; Carreno, Beatriz M; Petti, Allegra A et al. (2016) pVAC-Seq: A genome-guided in silico approach to identifying tumor neoantigens. Genome Med 8:11|
|McNulty, Samantha N; StrÃ¼be, Christina; Rosa, Bruce A et al. (2016) Dictyocaulus viviparus genome, variome and transcriptome elucidate lungworm biology and support future intervention. Sci Rep 6:20316|
|Pfefferle, Adam D; Agrawal, Yash N; Koboldt, Daniel C et al. (2016) Genomic profiling of murine mammary tumors identifies potential personalized drug targets for p53-deficient mammary cancers. Dis Model Mech 9:749-57|
|Zheng, Siyuan; Cherniack, Andrew D; Dewal, Ninad et al. (2016) Comprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma. Cancer Cell 29:723-36|
|Zhang, Jin; White, Nicole M; Schmidt, Heather K et al. (2016) INTEGRATE: gene fusion discovery using whole genome and transcriptome data. Genome Res 26:108-18|
|Camargo, M Constanza; Bowlby, Reanne; Chu, Andy et al. (2016) Validation and calibration of next-generation sequencing to identify Epstein-Barr virus-positive gastric cancer in The Cancer Genome Atlas. Gastric Cancer 19:676-81|
|Daiger, Stephen P; Sullivan, Lori S; Bowne, Sara J et al. (2016) Identification of a Novel Gene on 10q22.1 Causing Autosomal Dominant Retinitis Pigmentosa (adRP). Adv Exp Med Biol 854:193-200|
Showing the most recent 10 out of 179 publications